AstraZeneca posts CAPItello-281 results in PTEN-deficient prostate cancer; registers AZD4954 Phase 1
AstraZeneca reported results from a Phase III prostate cancer trial and posted a new early-phase pharmacokinetic study for AZD4954.
This week brought a results posting for a large AstraZeneca prostate cancer program and a newly listed early-phase study for an investigational compound.
- AstraZeneca's Phase III "CAPItello-281" trial tests capivasertib plus abiraterone against placebo plus abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer marked by PTEN deficiency.1 The study enrolled 1012 participants, reached primary completion on 2024-10-07, and results were first posted on 2026-09-10.1
- AstraZeneca, with collaborator Quotient Sciences, has registered a Phase 1 open-label study of radiolabelled AZD4954 in 8 healthy male participants per part, aged 30-65, at a single site in Nottingham, United Kingdom.2 The study will examine mass balance recovery, absorption, metabolism, and excretion of the carbon-14 labeled compound, along with its absolute bioavailability.2 The trial is not yet recruiting, with an estimated primary completion date of 2026-12-17.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.